Inside the Race to Solve America’s Concussion Crisis

Jake VanLandingham, Ph.D., a 45-year-old neuroscientist, has spent nearly a decade trying to develop a drug that he believes can heal concussions. “We’re virtual,” he likes to say of his eight-employee company, Prevacus, a UF Innovate | Sid Martin Biotech alum. In 2018, he says, he sold his family home to keep his startup alive. […]

Karen Zaderej, Chairman, CEO, and President of Axogen, Interviewed in Small-Cap Institute Podcast

Small-Cap Institute host Amanda Gerut interviews Karen Zaderej, chairman, CEO, and president of UF startup and UF Innovate | Sid Martin Biotech graduate company Axogen, a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves. Karen has been a part of Axogen since May 2006, serving as Vice President of Marketing and […]

Smartisan Technology Becomes Global Partner of Anti-Bacteria Technology Provider Sharklet

Niche smartphone brand Smartisan Technology, a Chinese multinational technology company headquartered in Beijing and Chengdu, announced global partnership with UF startup and UF Innovate | Sid Martin Biotech alum Sharklet Technologies Inc. It had been revealed that the partnership had nothing to do with smartphones, but was related to the medicare industry. “New technology, no matter […]

VetiOx Named Top Product of 2019 by Pet Business Magazine

University of Florida startup, UF Innovate | Sid Martin Biotech alum, and UF Innovate | The Hub resident company ReliOx Corporation, a specialty chemical technology company that specializes in introducing disruptive chemistries into critical industrial and general use applications, was featured in Pet Business Magazine with its product VetiOx as one of the top products […]

Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced the completion of enrollment in its ongoing double-blind, randomized, placebo-controlled Phase 2 trial of its lead product candidate, AG013, an easy-to-use oral rinsing […]

$6 Million Expansion for Gene Therapy Facility Completed at Alachua’s Progress Park

Local and state officials gathered in Alachua to commemorate a $6 million expansion at Progress Park. Representatives of Thermo Fisher Scientific Inc., a global science company involved with research and biotechnology product development, presented the company’s expanded gene therapy and viral vector services site. The day included tours of the 95,000-square-foot facility. University of Florida’s […]

Axogen Named to the Deloitte Technology Fast 500 List

For the sixth year in a row, UF startup and UF Innovate | Sid Martin Biotech graduate company Axogen, a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, was named to the Deloitte Technology Fast 500 list. The Deloitte Technology Fast 500 has been one of the […]

Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), announced the publication of the study titled “Complete synthesis of the bicyclic ring of a mutacin analog with orthogonally protected lanthionine via solid-phase intracyclization” […]

Arranta Bio Announces the Acquisition of Captozyme™, Creating a Center of Excellence for Microbiome Development and Clinical Supply

Arranta Bio, a contract development and manufacturing organization (CDMO), announced the acquisition of UF Innovate alumni startup Captozyme™, a leader in health care for and through the gut using novel enzymes and live biotherapeutics. With the acquisition, Arranta Bio will establish its Center of Excellence for process and analytical development and early clinical supply for […]